These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32050787)

  • 1. Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database.
    Louie KS; Banks V; Scholz F; Richter H; Öhrling K; Mohr P; Haferkamp S
    Future Oncol; 2020 Mar; 16(8):317-328. PubMed ID: 32050787
    [No Abstract]   [Full Text] [Related]  

  • 2. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.
    Andtbacka RHI; Amatruda T; Nemunaitis J; Zager JS; Walker J; Chesney JA; Liu K; Hsu CP; Pickett CA; Mehnert JM
    EBioMedicine; 2019 Sep; 47():89-97. PubMed ID: 31409575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.
    Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS
    Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries.
    van Akkooi ACJ; Haferkamp S; Papa S; Franke V; Pinter A; Weishaupt C; Huber MA; Loquai C; Richtig E; Gokani P; Öhrling K; Louie KS; Mohr P
    Adv Ther; 2021 Feb; 38(2):1245-1262. PubMed ID: 33368016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
    Corrigan PA; Beaulieu C; Patel RB; Lowe DK
    Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
    Ressler JM; Karasek M; Koch L; Silmbrod R; Mangana J; Latifyan S; Aedo-Lopez V; Kehrer H; Weihsengruber F; Koelblinger P; Posch C; Kofler J; Michielin O; Richtig E; Hafner C; Hoeller C
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.
    Fröhlich A; Niebel D; Fietz S; Egger E; Buchner A; Sirokay J; Landsberg J
    Cancer Immunol Immunother; 2020 May; 69(5):759-769. PubMed ID: 32052079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.
    Kelly CM; Antonescu CR; Bowler T; Munhoz R; Chi P; Dickson MA; Gounder MM; Keohan ML; Movva S; Dholakia R; Ahmad H; Biniakewitz M; Condy M; Phelan H; Callahan M; Wong P; Singer S; Ariyan C; Bartlett EK; Crago A; Yoon S; Hwang S; Erinjeri JP; Qin LX; Tap WD; D'Angelo SP
    JAMA Oncol; 2020 Mar; 6(3):402-408. PubMed ID: 31971541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions.
    Larocca CA; LeBoeuf NR; Silk AW; Kaufman HL
    Am J Clin Dermatol; 2020 Dec; 21(6):821-832. PubMed ID: 32767272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma.
    Haitz K; Khosravi H; Lin JY; Menge T; Nambudiri VE
    J Am Acad Dermatol; 2020 Jul; 83(1):189-196. PubMed ID: 32004650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.
    Barker CA; D'Angelo SP; Wasilewski G; Steckler AM; Lian M; Zhang Z; Chapman PB; Shoushtari AN; Ariyan CE
    Radiother Oncol; 2024 Nov; 200():110478. PubMed ID: 39159678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
    Kohlhapp FJ; Zloza A; Kaufman HL
    Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
    Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
    J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
    Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
    Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
    Gangi A; Zager JS
    Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.
    Chesney JA; Puzanov I; Collichio FA; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan T; Hauschild A; Lebbé C; Joshi H; Snyder W; Mehnert JM
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37142291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience.
    Carr MJ; Sun J; DePalo D; Rothermel LD; Song Y; Straker RJ; Baecher K; Louie RJ; Stahlie EHA; Wright GP; Naqvi SMH; Kim Y; Sarnaik AA; Karakousis GC; Lowe MC; Delman KA; van Akkooi ACJ; Ollila DW; Collichio F; Zager JS
    Ann Surg Oncol; 2022 Feb; 29(2):791-801. PubMed ID: 34648098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model.
    Stahlie EHA; Franke V; Zuur CL; Klop WMC; van der Hiel B; Van de Wiel BA; Wouters MWJM; Schrage YM; van Houdt WJ; van Akkooi ACJ
    Cancer Immunol Immunother; 2021 Aug; 70(8):2291-2300. PubMed ID: 33507342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a).
    Franke V; Berger DMS; Klop WMC; van der Hiel B; van de Wiel BA; Ter Meulen S; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
    Int J Cancer; 2019 Aug; 145(4):974-978. PubMed ID: 30694555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.
    Puzanov I; Milhem MM; Minor D; Hamid O; Li A; Chen L; Chastain M; Gorski KS; Anderson A; Chou J; Kaufman HL; Andtbacka RH
    J Clin Oncol; 2016 Aug; 34(22):2619-26. PubMed ID: 27298410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.